Fixed-Dose Combination Treatment after Stroke for Secondary Prevention in China

Stroke

Volumn 46, Issue 5, 2015, Pages 1295-1300

  Longde, Wang ^a   Ling, Yin ^b   Yang, Hua ^c   Yi, Zuo ^f   Yongjun, Wang ^e   Xunming, Ji ^d   Xiaoyuan, Niu ^g   Qiumin, Qu ^h   Li, He ⁱ   Yuming, Xu ^j   Mei, Li ^b   Jiayi, Sun ^k   Jing, Liu ^k   Dong, Zhao ^k  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f Health and Family planning Commission of Shandong Province   (China)

^g SHANXI MEDICAL UNIVERSITY   (China)

^h XI'AN JIAOTONG UNIVERSITY   (China)

ⁱ SICHUAN UNIVERSITY   (China)

^j THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^k CAPITAL MEDICAL UNIVERSITY   (China)

more..

Author keywords

cardiovascular diseases; prevention; risk factors; stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CARDIOVASCULAR AGENT; DRUG COMBINATION;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CHINA; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; RISK FACTOR; SECONDARY PREVENTION; STROKE PATIENT; SYSTOLIC BLOOD PRESSURE; VERY ELDERLY; AGE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG COMBINATION; PROCEDURES; SOCIOECONOMICS; STROKE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHINA; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK FACTORS; SECONDARY PREVENTION; SOCIOECONOMIC FACTORS; STROKE;

EID: 84933496784     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.007384     Document Type: Article

References (23)

1. De Gates An, Farr MRB, Wright N, Jarvis MC, Rees K, Ebrahim S, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014;4:CD009868.
2. Sanz G, Fuster V. Prevention: Polypills for cardiovascular prevention: a step forward? Nat Rev Cardiol. 2013;10:683-684. doi: 10.1038/nrcardio.2013.157.
3. Huffman MD, Yusuf S. Polypills: essential medicines for cardiovascular disease secondary prevention? J Am Coll Cardiol. 2014;63:1368-1370. doi: 10.1016/j.jacc.2013.08.1665.
4. Gaziano JM. Progress with the polypill? JAMA. 2013;310:910-911. doi: 10.1001/jama.2013.277066.
5. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al; UMPIRE Collaborative Group. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310:918-929. doi: 10.1001/jama.2013.277064.
6. World Health Organization. Secondary Prevention of Noncommunicable Disease in Low and Middle Income Countries Through Community-Based and Health Service Interventions. Geneva: World Health Organization; 2002. http://www.who.int/cardiovascular-diseases/media/en/615.pdf. Accessed November 24, 2014.
7. Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013;381:1987-2015. doi: 10.1016/S0140-6736(13)61097-1.
8. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231-1243. doi: 10.1016/S0140-6736(11)61215-4.
9. Chen Y, Li L, Zhang Q, Clarke R, Chen J, Guo Y, et al; China Kadoorie Biobank Study. Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people. Int J Cardiol. 2014;172:88-95. doi: 10.1016/j.ijcard.2013.12.065.
10. Zhao D, Liu J, Wang W, Zeng Z, Cheng J, Liu J, et al. Epidemiological transition of stroke in China: twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke. 2008;39:1668-1674. doi: 10.1161/STROKEAHA.107.502807.
11. Huffman MD, Rao KD, Pichon-Riviere A, Zhao D, Harikrishnan S, Ramaiya K, et al. A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low-and middleincome countries. PLoS One. 2011;6:e20821. doi: 10.1371/journal. pone.0020821.
12. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al; American Heart Association; American Stroke Association. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008;39:1647-1652. doi: 10.1161/STROKEAHA.107.189063.
13. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. 2011;42:227-276. doi: 10.1161/STR.0b013e3181f7d043.
14. Asplund K, Tuomilehto J, Stegmayr B, Wester PO, Tunstall-Pedoe H. Diagnostic criteria and quality control of the registration of stroke events in the MONICA project. Acta Med Scand Suppl. 1988;728:26-39.
15. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet. 2000;355:675-687.
16. Liu LS; Writing Group of 2010 Chinese Guideline for the Management of Hypertension. 2010 Chinese guidelines for the management of hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39:579-615. (English abstract is available in Pubmed and the article in Chinese.)
17. Expert Dyslipidemia Panel, Grundy SM. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. J Clin Lipidol. 2013;7:561-565. doi: 10.1016/j. jacl.2013.10.001.
18. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
19. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000;19:1141-1164.
20. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:2160-2236. doi: 10.1161/STR.0000000000000024.
21. Center for Health Statistics and Information MOH. An Analysis Report of National Health Services Survey in 2003 (in Chinese). Beijing, China: Peking Union Medical College Publishing House; 2004.
22. Peng B, Ni J, Anderson CS, Zhu Y, Wang Y, Pu C, et al; SMART Investigators. Implementation of a structured guideline-based program for the secondary prevention of ischemic stroke in China. Stroke. 2014;45:515-519. doi: 10.1161/STROKEAHA.113.001424.
23. Moran A, Gu D, Zhao D, Coxson P, Wang YC, Chen CS, et al. Future cardiovascular disease in China: markov model and risk factor scenario projections from the coronary heart disease policy model-China. Circ Cardiovasc Qual Outcomes. 2010;3:243-252. doi: 10.1161/CIRCOUTCOMES.109.910711.